Lifevantage Corporation Common Stock (Delaware) (LFVN)
LFVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$5.95
-0.50% on the day
Market cap
$74.9M
Micro cap
Revenue · 2025
$228.5M
+14.2% on 2024
Net income · 2025
$9.8M
4.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LFVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000849146 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | COLORADO |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $228.5M |
| Net income | $9.8M |
| Operating income | $12.2M |
| Net margin | 4.3% |
| Operating margin | 5.3% |
| Revenue growth | +14.2% |
| Cash | Not in SEC XBRL data |
| Total assets | $61.2M |
| P/E (computed) | 7.6× |
| P/S (computed) | 0.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-10 |
| Latest annual report | 10-K | 2026-08-27 |
| Latest quarterly / interim | 10-Q | 2026-05-06 |
| Latest current report | 8-K | 2026-10-05 |
| Latest proxy | DEFA14A | 2026-09-18 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics Inc. | $1.75 | -7.89% | $75.0M |
| INCR | Intercure Ltd. | $5.03 | +1.62% | $75.5M |
| HRTX | Heron Therapeutics Inc. | $0.3906 | -6.01% | $74.2M |
| MNOV | Medicinova Inc | $1.50 | -2.60% | $73.8M |
| CTOR | Citius Oncology Inc. | $0.7920 | -2.54% | $73.6M |
| NTHI | NeOnc Technologies Holdings Inc. | $2.60 | -4.95% | $77.2M |
| RFL | Rafael Holdings Inc. | $1.49 | -1.97% | $77.5M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $8.66 | -8.36% | $77.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier